Results 101 to 110 of about 61,558 (234)

The Imbalance Between Tumor Immunosurveillance and Tumor Immune Escape in Glioblastoma

Immunology &Cell Biology, EarlyView.
(Left)The identification and elimination of tumour cells is enabled by the infiltration of functional innate and adaptive immune effectors into the TME, such as natural killer cells (NK cells) and cytotoxic T cells (CD8 T cells). Effective innate and adaptive immune responses facilitate immunological control of malignant outgrowth.
Sarah J. MacDonald, Matthew Drill, Padmakrishnan C. Jayakrishnan, Richard P. Sequeira, Terence J. O'Brien, Rosalind L. Jeffree, Mastura Monif   +6 more
wiley   +1 more source

DPYD and UGT1A1 Genotype‐Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant‐Specific Impact on Treatment Intensity and Toxicity

International Journal of Cancer, Volume 159, Issue 10, Page 2512-2524, 15 November 2026.
Pre‐treatment DPYD and UGT1A1 genotyping is increasingly used to prevent fluoropyrimidine‐ and irinotecan‐related toxicity, but variant‐specific real‐world effects remain unclear. In an unselected cohort of cancer patients with actionable genotypes, genotype‐driven dosing improved safety while preserving treatment exposure in high‐risk DPYD c.1905+1G>A
Martina Gambron, Elena Peruzzi, Samantha Perfler, Marcella Montico, Riccardo Cecchin, Elena De Mattia, Michele Spina, Camilla Lisanti, Serena Corsetti, Luisa Foltran, Fabio Puglisi, Rossana Roncato, Erika Cecchin   +12 more
wiley   +1 more source

Inhibition of NHE1 Overcomes Temozolomide-Resistance in Glioblastoma via ROS-AKT/ERK Axis-Mediated Autophagy Suppression. [PDF]

J Biochem Mol Toxicol
NHE1 inhibition via HOE‐642 suppresses autophagy through the ROS‐AKT/ERK axis, reversing temozolomide resistance in glioblastoma by disrupting the autophagy‐apoptosis balance and enhancing TMZ sensitivity in vitro and in vivo. ABSTRACT Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with temozolomide (TMZ) resistance being a ...
Li D, Li Y, Zheng X, Wang Z, Wang Y, Zhang J, Guo J, Wang L, Li J, Liu Y, Li Y.   +10 more
europepmc   +2 more sources

Application and advance of temozolomide in the treatment of pituitary adenomas

Chinese Journal of Contemporary Neurology and Neurosurgery, 2015
Pituitary adenoma is a common primary tumor in central nervons system. The aggressive pituitary adenomas show invasive characteristics with higher recurrence rate and worse prognosis, which normally need the comprehensive therapy of surgery ...
Yi-guang LIN, Xiao-min LIU
doaj  

Real‐World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond

International Journal of Cancer, Volume 159, Issue 7, Page 1780-1787, 1 October 2026.
Progression after anti‐PD‐1‐based therapy is a predominant scenario in metastatic melanoma. However, real‐world data informing treatment of metastatic melanoma in later lines remains scarce. This retrospective nationwide, population‐based cohort study shows in a real‐world setting that nivolumab plus ipilimumab can induce durable responses beyond the ...
Yago Garitaonaindia, Søren Kjær Petersen, Louise M. Guldbrandt, Troels H. Borch, Christina H. Ruhlmann, Rasmus Blechingberg Friis, Adam A. Luczak, Lars Bastholt, Henrik Schmidt, Inge Marie Svane, Eva Ellebaek, Marco Donia   +11 more
wiley   +1 more source

Harnessing Natural Killer Cells: From Neuroimmunology to Novel Therapies for Central Nervous System Diseases

MedComm, Volume 7, Issue 10, October 2026.
This review delineates the multifaceted roles of natural killer (NK) cells in the central nervous system, spanning direct cytolysis, immunoregulation, and crosstalk with the brain microenvironment. We evaluate the translational potential and challenges of NK cell immunotherapies for a spectrum of neurological conditions.
Kaihang Deng, Wai Po Chong
wiley   +1 more source

Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool. [PDF]

J Nucl Med
Jeanjean P, Swaidan A, Tse C, Kwock S, Fajnorova I, Dove R, Azrour IC, Taylor S, Comin-Anduix B, Nathanson DA, Carlucci G, Calais J, Czernin J, Besserer-Offroy É, Mona CE.   +14 more
europepmc   +1 more source

Feasibility of Spin‐ and Gradient‐Echo Dynamic Susceptibility Contrast MRI for Microvascular Characterization at 7 Tesla

NMR in Biomedicine, Volume 39, Issue 10, October 2026.
Spin‐ and‐gradient‐echo DSC MRI at 7 T allows for characterization of the microvasculature at an improved resolution and a reduced gadolinium‐based contrast agent dosage while maintaining increased vascular contrast. Ratios between normal‐appearing gray matter and white matter for relative cerebral blood volume and vessel size estimates were similar ...
Karen N. van der Werff, Daniëlle van Dorth, Krishnapriya Venugopal, Esther A. H. Warnert, Dirk H. J. Poot, Frans M. Vos, Marion Smits, Stefan Klein, C. Chad Quarles, Juan A. Hernandez‐Tamames, Johan A. F. Koekkoek, Jeroen de Bresser, Matthias J. P. van Osch   +12 more
wiley   +1 more source

A Blood–Brain Barrier‐Permeable Guanylhydrazone Analogue of the ASIC3 Activator GMQ Inhibits Human Glioblastoma Stem Cell Growth In Vitro

ChemMedChem, Volume 21, Issue 18, 28 September 2026.
The acid‐sensing ion channel 3 (ASIC3), physiologically located in the peripheral nervous system, was found in stem cells of CNS‐located glioblastoma multiforme (GBM CSCs); its chronic activation in the CNS kills dysfunctional GBM CSCs with no effect on ASIC3‐lacking CNS tissues.
Leonardo Maiorana, Nicoletta Collura, Andrea Gotti, Giulia De Leonardis, Greta Donati, Alice Maiocchi, Luciana Marinelli, Andrea Menegon, Pierfausto Seneci   +8 more
wiley   +1 more source

Temozolomide and olaparib for the treatment of an ARID1A-mutated uterine carcinosarcoma: A case report. [PDF]

Gynecol Oncol Rep
Liu C, Abozenah Y, Rutherford TJ, Andikyan V, Kohut A, Anderson ML.   +5 more
europepmc   +1 more source